^
    8d
    ATHENA-1: A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=107, Recruiting, Regeneron Pharmaceuticals | Trial completion date: May 2029 --> Jan 2030 | Trial primary completion date: Jun 2027 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    Ordspono (odronextamab) • REGN5837
    3years
    TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (EHA 2023)
    This Phase 1, open-label, first-in-human study will assess the safety and tolerability of REGN5837 in combinationwith odronextamab in patients with R/R aggressive B-NHL.
    Clinical • P1 data • Combination therapy
    |
    CD22 (CD22 Molecule)
    |
    Ordspono (odronextamab) • REGN5837